AU2005297303B2 - Novel diagnostic kit for malignant melanoma - Google Patents
Novel diagnostic kit for malignant melanoma Download PDFInfo
- Publication number
- AU2005297303B2 AU2005297303B2 AU2005297303A AU2005297303A AU2005297303B2 AU 2005297303 B2 AU2005297303 B2 AU 2005297303B2 AU 2005297303 A AU2005297303 A AU 2005297303A AU 2005297303 A AU2005297303 A AU 2005297303A AU 2005297303 B2 AU2005297303 B2 AU 2005297303B2
- Authority
- AU
- Australia
- Prior art keywords
- sparc
- melanoma
- gpc3
- protein
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 201000001441 melanoma Diseases 0.000 title claims abstract description 110
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 title claims abstract description 14
- 238000009007 Diagnostic Kit Methods 0.000 title claims abstract description 12
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims abstract description 6
- 102100032530 Glypican-3 Human genes 0.000 claims abstract 5
- 210000002966 serum Anatomy 0.000 claims description 31
- 238000002405 diagnostic procedure Methods 0.000 claims description 12
- 210000002381 plasma Anatomy 0.000 claims description 5
- 210000003296 saliva Anatomy 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 17
- 238000003745 diagnosis Methods 0.000 abstract description 10
- 239000000439 tumor marker Substances 0.000 abstract description 9
- 238000013399 early diagnosis Methods 0.000 abstract description 4
- 102100037599 SPARC Human genes 0.000 description 109
- 102000010956 Glypican Human genes 0.000 description 51
- 108050001154 Glypican Proteins 0.000 description 50
- 108050007237 Glypican-3 Proteins 0.000 description 50
- 210000004027 cell Anatomy 0.000 description 21
- 206010028980 Neoplasm Diseases 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 9
- SXISMOAILJWTID-UHFFFAOYSA-N 5-S-cysteinyldopa Chemical compound OC(=O)C(N)CSC1=CC(CC(N)C(O)=O)=CC(O)=C1O SXISMOAILJWTID-UHFFFAOYSA-N 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 102100022185 Melanoma-derived growth regulatory protein Human genes 0.000 description 7
- 101710195116 Melanoma-derived growth regulatory protein Proteins 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 208000030457 superficial spreading melanoma Diseases 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 239000004568 cement Substances 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000002752 melanocyte Anatomy 0.000 description 4
- 230000037311 normal skin Effects 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000002980 postoperative effect Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- 206010000583 acral lentiginous melanoma Diseases 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 201000000849 skin cancer Diseases 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102100023849 Glycophorin-C Human genes 0.000 description 2
- 208000007256 Nevus Diseases 0.000 description 2
- 108010077077 Osteonectin Proteins 0.000 description 2
- 102000009890 Osteonectin Human genes 0.000 description 2
- 102000040739 Secretory proteins Human genes 0.000 description 2
- 108091058545 Secretory proteins Proteins 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012340 reverse transcriptase PCR Methods 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101150051208 HSPH1 gene Proteins 0.000 description 1
- 102100031624 Heat shock protein 105 kDa Human genes 0.000 description 1
- 101000881168 Homo sapiens SPARC Proteins 0.000 description 1
- 101100478240 Homo sapiens SPARC gene Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 206010024218 Lentigo maligna Diseases 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101100478241 Mus musculus Sparc gene Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000009077 Pigmented Nevus Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 102000048373 human GPC3 Human genes 0.000 description 1
- 102000045436 human SPARC Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 208000011080 lentigo maligna melanoma Diseases 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000023578 negative regulation of cell adhesion Effects 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000004906 toe nail Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4722—Proteoglycans, e.g. aggreccan
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4727—Calcium binding proteins, e.g. calmodulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004303688 | 2004-10-19 | ||
| JP2004-303688 | 2004-10-19 | ||
| PCT/JP2005/014567 WO2006043362A1 (ja) | 2004-10-19 | 2005-08-09 | 悪性黒色腫（メラノーマ）の新規な診断キット |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2005297303A1 AU2005297303A1 (en) | 2006-04-27 |
| AU2005297303B2 true AU2005297303B2 (en) | 2011-11-10 |
Family
ID=36202786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005297303A Ceased AU2005297303B2 (en) | 2004-10-19 | 2005-08-09 | Novel diagnostic kit for malignant melanoma |
Country Status (6)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101313063B (zh) | 2005-08-09 | 2013-04-03 | 肿瘤疗法·科学股份有限公司 | 用于hla-a2阳性人群的来自磷脂酰肌醇蛋白聚糖-3(gpc3)的癌症排斥抗原肽以及含有该肽的药物 |
| CA2655361C (en) * | 2006-06-16 | 2014-10-07 | Kumamoto University | Sparc-derived tumor rejection antigenic peptides and medicaments comprising the same |
| EP2294216A4 (en) | 2008-05-14 | 2011-11-23 | Dermtech Int | DIAGNOSIS OF MELANOMA AND SOLAR LENTIGO BY ANALYSIS OF NUCLEIC ACIDS |
| CN102281890B (zh) * | 2008-12-05 | 2014-08-20 | 阿布拉西斯生物科学有限责任公司 | Sparc结合肽及其应用 |
| BR112012008316A2 (pt) * | 2009-09-18 | 2017-06-06 | Abraxis Bioscience Llc | utilização da assinatura microambiente sparc no tratamento de câncer |
| EP3085387A1 (en) * | 2010-04-26 | 2016-10-26 | Abraxis BioScience, LLC | Sparc binding antibodies and uses thereof |
| US9193782B2 (en) | 2010-06-03 | 2015-11-24 | Abraxis Bioscience, Llc | Use of the SPARC microenvironment signature in the treatment of cancer |
| US20130281376A1 (en) * | 2010-10-08 | 2013-10-24 | Abraxis Bioscience, Llc | Sparc microenvironment signature, plasma sparc, and ldh as prognostic biomarkers in the treatment of cancer |
| AU2013278452A1 (en) | 2012-06-18 | 2015-01-29 | Lsip, Llc | Kit for diagnosing malignant melanoma |
| US20140314697A1 (en) * | 2013-04-18 | 2014-10-23 | Corum Inc. | Method for Inhibiting Inflammation and Reducing Melanophilin Expression with Glycine Derivatives And the Composition Thereof |
| US20150005184A1 (en) * | 2013-06-28 | 2015-01-01 | Dermtech International | Diagnosis of melanoma by nucleic acid analysis |
| US11976332B2 (en) | 2018-02-14 | 2024-05-07 | Dermtech, Inc. | Gene classifiers and uses thereof in non-melanoma skin cancers |
| CA3134936A1 (en) | 2019-03-26 | 2020-10-01 | Dermtech, Inc. | Novel gene classifiers and uses thereof in skin cancers |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU766544B2 (en) * | 1998-06-06 | 2003-10-16 | Genostic Pharma Limited | Probes used for genetic profiling |
| WO2004005883A2 (en) * | 2002-07-02 | 2004-01-15 | The Johns Hopkins University | Secreted and cytoplasmic tumor endothelial markers |
| DK1536006T3 (da) * | 2002-08-30 | 2011-10-17 | Medinet Co Ltd | Cancerantigener og anvendelse deraf |
| EP2325338B1 (en) * | 2003-07-17 | 2015-01-21 | Pacific Edge Limited | Markers for detection of gastric cancer |
| WO2005039380A2 (ja) * | 2003-10-29 | 2005-05-06 | Kumamoto Tech & Ind Found | 悪性黒色腫（メラノーマ）の診断剤 |
-
2005
- 2005-08-09 WO PCT/JP2005/014567 patent/WO2006043362A1/ja active Application Filing
- 2005-08-09 EP EP05770440A patent/EP1813943B1/en not_active Expired - Lifetime
- 2005-08-09 AU AU2005297303A patent/AU2005297303B2/en not_active Ceased
- 2005-08-09 DE DE602005016831T patent/DE602005016831D1/de not_active Expired - Lifetime
- 2005-08-09 US US11/577,435 patent/US8017345B2/en not_active Expired - Fee Related
- 2005-08-09 JP JP2006542257A patent/JP4834839B2/ja not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| LEDDA, F. et al. The Journal of Investigative Dermatology. 1997, vol. 108(2), pages 210-214 * |
| NAKATSURA, T. et al. Clinical Cancer Research. vol. 10, pages 6612-6621 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005297303A1 (en) | 2006-04-27 |
| JPWO2006043362A1 (ja) | 2008-05-22 |
| JP4834839B2 (ja) | 2011-12-14 |
| WO2006043362A1 (ja) | 2006-04-27 |
| EP1813943A4 (en) | 2007-12-12 |
| EP1813943B1 (en) | 2009-09-23 |
| US8017345B2 (en) | 2011-09-13 |
| DE602005016831D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2009-11-05 |
| US20090111095A1 (en) | 2009-04-30 |
| EP1813943A1 (en) | 2007-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5006802B2 (ja) | 上皮由来の癌診断および予後診断のためのバイオマーカーとしてのＣｙｒ６１ | |
| Jou et al. | Salivary zinc finger protein 510 peptide as a novel biomarker for detection of oral squamous cell carcinoma in early stages | |
| JP4594575B2 (ja) | がんのマーカーとして使用されるアネキシン類及び自己抗体 | |
| AU2005297303B2 (en) | Novel diagnostic kit for malignant melanoma | |
| CN101421622A (zh) | 作为癌症生物标志物的游离ngal | |
| KR20130102688A (ko) | 유방암 진단용 다중 바이오마커 세트, 이의 검출 방법 및 이에 대한 항체를 포함하는 유방암 진단키트 | |
| Hamrita et al. | An elongation factor-like protein (EF-Tu) elicits a humoral response in infiltrating ductal breast carcinomas: an immunoproteomics investigation | |
| KR20120057562A (ko) | 피브린 및 피브리노겐 분해 생성물의 검출 및 관련된 제조 방법 및 암의 검출 및 모니터링을 위한 용도 | |
| US8642347B2 (en) | Urinary CA125 peptides as biomarkers of ovarian cancer | |
| JP2739110B2 (ja) | ヒト乳ガンの分析 | |
| KR101486548B1 (ko) | 나이관련 황반변성 진단용 마커 및 이를 이용한 나이 관련 황반 변성 진단 방법 | |
| KR101311717B1 (ko) | 대장암 진단용 단백질 마커 멜라노트랜스페린 및 이에 대한 항체를 포함하는 대장암 진단 키트 | |
| AU2004283614B2 (en) | Diagnostic agent for malignant melanoma | |
| KR102141546B1 (ko) | 난청 예후 예측방법 및 이를 이용한 키트 | |
| KR100896328B1 (ko) | 대사성 질환의 진단 마커로 유용한 프로그레뉼린 | |
| US20130040325A1 (en) | Enzyme Linked Immunosorbent Assay (ELISA) Method and Kit for Detecting Soluble Programmed Cell Death Protein 5 (PDCD5) | |
| KR20120021518A (ko) | 간암 진단용 조성물 및 진단방법 | |
| JP7565046B2 (ja) | がんの骨転移を検出する方法及び検出試薬 | |
| KR101431063B1 (ko) | 유방암 진단용 단백질 마커 아포리포단백질 ｃ-1, 이의 검출 방법 및 이에 대한 항체를 포함하는 유방암 진단키트 | |
| KR100991289B1 (ko) | 유방암 진단용 ａ２―ＨＳ 당단백질에 대한 자가항체마커및 진단키트 | |
| AU2001247317A1 (en) | A lysosomal pepstatin-insensitive proteinase as a novel biomarker for detecting and diagnosing breast cancer | |
| JP2010139293A (ja) | 早期癌腫瘍マーカー |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: LSIP, LLC Free format text: FORMER APPLICANT(S): KUMAMOTO UNIVERSITY |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |